| scholarly article | Q13442814 |
| P50 | author | Jean-Antoine Girault | Q33122764 |
| Jean-Christophe Corvol | Q43071395 | ||
| Cristina Alcacer | Q56501547 | ||
| Denis Hervé | Q89045564 | ||
| Khadija Tahiri | Q94523907 | ||
| Chuansong Wang | Q94523909 | ||
| P2093 | author name string | Wassila Carpentier | |
| Paul F Worley | |||
| Desheng Xu | |||
| Matthew During | |||
| Fanny Charbonnier-Beaupel | |||
| Marion Malerbi | |||
| P2860 | cites work | Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements | Q24632752 |
| Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources | Q27860739 | ||
| Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists | Q28131785 | ||
| Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease | Q28377680 | ||
| Neuronal pentraxins mediate synaptic refinement in the developing visual system | Q28591007 | ||
| TM4: a free, open-source system for microarray data management and analysis | Q29547339 | ||
| D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons | Q29615480 | ||
| Loss of Nocturnin, a circadian deadenylase, confers resistance to hepatic steatosis and diet-induced obesity | Q30443685 | ||
| Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease | Q30493275 | ||
| Dichotomous dopaminergic control of striatal synaptic plasticity | Q30493521 | ||
| Narp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons | Q30496836 | ||
| Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. | Q30594829 | ||
| Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. | Q30783824 | ||
| Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. | Q30886204 | ||
| Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia | Q30988635 | ||
| Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. | Q31039577 | ||
| Nedd4-like proteins: an emerging family of ubiquitin-protein ligases implicated in diverse cellular functions | Q33632965 | ||
| Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum | Q33723743 | ||
| Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia | Q33758221 | ||
| Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. | Q33817654 | ||
| Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. | Q33890236 | ||
| Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? | Q34044620 | ||
| Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors | Q34093012 | ||
| Maladaptive striatal plasticity in L-DOPA-induced dyskinesia | Q34094008 | ||
| Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice | Q34490801 | ||
| Dopamine- and cAMP-regulated phosphoprotein of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in experimental parkinsonism | Q36201811 | ||
| Dopamine-mediated regulation of corticostriatal synaptic plasticity. | Q36762821 | ||
| Differences between dorsal and ventral striatum in Drd1a dopamine receptor coupling of dopamine- and cAMP-regulated phosphoprotein-32 to activation of extracellular signal-regulated kinase | Q36978965 | ||
| Neuronal pentraxins modulate cocaine-induced neuroadaptations. | Q37028692 | ||
| mGluR1/5-dependent long-term depression requires the regulated ectodomain cleavage of neuronal pentraxin NPR by TACE. | Q37239438 | ||
| Molecular mechanisms of L-DOPA-induced dyskinesia | Q37247578 | ||
| Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia | Q37674269 | ||
| The Role of AMPAR Trafficking Mediated by Neuronal Pentraxins in Cocaine-induced Neuroadaptations. | Q39774189 | ||
| Neuronal pentraxin II is highly upregulated in Parkinson's disease and a novel component of Lewy bodies | Q41847718 | ||
| Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia. | Q42459246 | ||
| A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function | Q42463405 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| G(olf) and Gs in rat basal ganglia: possible involvement of G(olf) in the coupling of dopamine D1 receptor with adenylyl cyclase | Q42511423 | ||
| Dopamine depletion induces distinct compensatory gene expression changes in DARPP-32 signal transduction cascades of striatonigral and striatopallidal neurons | Q42579414 | ||
| l-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata | Q42927205 | ||
| Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease | Q43067885 | ||
| Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. | Q43198758 | ||
| Development and optimization of adeno-associated virus vector transfer into the central nervous system | Q43943045 | ||
| Synaptically targeted narp plays an essential role in the aggregation of AMPA receptors at excitatory synapses in cultured spinal neurons. | Q44012243 | ||
| D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. | Q44037073 | ||
| Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia | Q44383212 | ||
| Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. | Q45007596 | ||
| Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. | Q45130529 | ||
| The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea | Q45303470 | ||
| Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. | Q45923687 | ||
| Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. | Q45928216 | ||
| Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. | Q45972521 | ||
| De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat. | Q46114297 | ||
| L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice | Q46136644 | ||
| The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease | Q46628501 | ||
| ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice | Q46684571 | ||
| Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA. | Q46750632 | ||
| A complex program of striatal gene expression induced by dopaminergic stimulation. | Q47892574 | ||
| Narp, a novel member of the pentraxin family, promotes neurite outgrowth and is dynamically regulated by neuronal activity. | Q48064825 | ||
| Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. | Q48092290 | ||
| Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia | Q48124096 | ||
| Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity | Q48236936 | ||
| Gα(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia. | Q48545028 | ||
| Variations in the "on-off" phenomenon | Q48600095 | ||
| L-DOPA Impairs Proteasome Activity in Parkinsonism through D1 Dopamine Receptor | Q61761448 | ||
| Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity | Q63256021 | ||
| Tyrosine hydroxylase-like immunoreactive neurons in the striatum of the rat | Q69367796 | ||
| Dopamine-receptor stimulation: biobehavioral and biochemical consequences | Q73125101 | ||
| Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment | Q73222097 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dyskinesia | Q629444 |
| P304 | page(s) | 96-111 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Journal of Neuroscience | Q1709864 |
| P1476 | title | Gene expression analyses identify Narp contribution in the development of L-DOPA-induced dyskinesia | |
| P478 | volume | 35 |
| Q37689486 | Antidyskinetic Effects of MEK Inhibitor Are Associated with Multiple Neurochemical Alterations in the Striatum of Hemiparkinsonian Rats |
| Q30836713 | Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy. |
| Q37241754 | Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia |
| Q50592833 | Dysregulation of BET proteins in levodopa-induced dyskinesia. |
| Q92445892 | L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning |
| Q57176638 | MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients |
| Q39403550 | Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications |
| Q93359665 | Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model |
| Q38438454 | Sideroflexin 3 is an α-synuclein-dependent mitochondrial protein that regulates synaptic morphology |
| Q49357267 | Signal transduction in L-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression |
| Q92861494 | The Role of Neuronal Pentraxin 2 (NP2) in Regulating Glutamatergic Signaling and Neuropathology |
| Q41297120 | Transcriptome profiling of the subventricular zone and dentate gyrus in an animal model of Parkinson's disease |
| Q39012371 | l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role? |
| Q38951947 | l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements? |
Search more.